Compugen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Compugen and other ETFs, options, and stocks.

About CGEN

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. 

CEO
Eran Ophir
CEOEran Ophir
Employees
75
Employees75
Headquarters
Holon, Tel Aviv
HeadquartersHolon, Tel Aviv
Founded
1993
Founded1993
Employees
75
Employees75

CGEN Key Statistics

Market cap
197.62M
Market cap197.62M
Price-Earnings ratio
5.52
Price-Earnings ratio5.52
Dividend yield
Dividend yield
Average volume
420.30K
Average volume420.30K
High today
$2.16
High today$2.16
Low today
$2.00
Low today$2.00
Open price
$2.00
Open price$2.00
Volume
190.62K
Volume190.62K
52 Week high
$2.38
52 Week high$2.38
52 Week low
$1.13
52 Week low$1.13

Stock Snapshot

The current Compugen(CGEN) stock price is $2.08, with a market capitalization of 197.62M. The stock trades at a price-to-earnings (P/E) ratio of 5.52.

As of 2026-03-07, Compugen(CGEN) stock has fluctuated between $2.00 and $2.16. The current price stands at $2.08, placing the stock +4.2% above today's low and -3.7% off the high.

Compugen(CGEN) shares are trading with a volume of 190.62K, against a daily average of 420.3K.

In the last year, Compugen(CGEN) shares hit a 52-week high of $2.38 and a 52-week low of $1.13.

In the last year, Compugen(CGEN) shares hit a 52-week high of $2.38 and a 52-week low of $1.13.

CGEN News

TipRanks 4d
Compugen Earnings Call: Cash Windfall, Trials and Risks

Compugen ((CGEN)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and po...

The Motley Fool 5d
Compugen Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Monday, March 2, 2026 at 8:30 a.m. ET Call participants Chief Executive Officer — Eran Ophir Executive Chair — Anat Cohen-Dayag...

Compugen Q4 2025 Earnings Call Transcript
TipRanks 5d
Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress

Compugen ( (CGEN) ) has issued an update. Compugen on March 2, 2026, reported fourth-quarter and full-year 2025 results that showcased a dramatically strengthe...

More CGEN News

TipRanks 5d
Compugen reports Q4 EPS 60c vs. (7c) last year

Reports Q4 revenue $67.3M vs. $1.5M last year. “We delivered important progress in 2025, highlighted by the extension of our cash runway into 2029 through a non...

People also own

Based on the portfolios of people who own CGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.